Core Viewpoint - The company has established a long-term incentive mechanism to ensure the successful implementation of the 2025 A-share option plan, aiming to enhance management performance and maximize shareholder interests [1][2]. Group 1: Assessment Objectives and Principles - The purpose of the assessment is to improve corporate governance and establish a long-term incentive mechanism to ensure the achievement of the company's strategic and operational goals by 2025 [1]. - The assessment must adhere to principles of fairness, openness, and impartiality, linking the A-share option plan closely with the performance and contributions of the incentivized individuals [1][2]. Group 2: Assessment Scope and Organization - The assessment applies to all individuals participating in the 2025 A-share option plan [1]. - The company's Board of Directors' Compensation and Assessment Committee will lead and organize the assessment work [1]. Group 3: Assessment Indicators and Standards - The assessment will evaluate the company's financial performance indicators annually, focusing on "net profit attributable to shareholders" and "revenue from innovative drugs" [1][2]. - Specific targets for the assessment indicators include a net profit target of 33.2 billion RMB for the first year, increasing to 39.6 billion RMB and 47.7 billion RMB in subsequent years [2][3]. Group 4: Assessment Period and Frequency - The assessment period spans from 2025 to 2027, with evaluations conducted annually [3][4]. Group 5: Assessment Procedures and Results Management - The Human Resources Department, under the guidance of the Compensation and Assessment Committee, is responsible for the assessment process and maintaining the results [4]. - Incentivized individuals have the right to understand their assessment results and can appeal if they disagree with the evaluations, following the established procedures [4].

Core Points - The company has proposed a stock option incentive plan for 2025, aiming to enhance corporate governance and retain talent [9][10][12] - The total number of stock options to be granted is capped at 5,726,100, representing approximately 0.2144% of the company's total shares [14][15] - The plan includes an initial grant of 4,580,900 options (80% of the total) and a reserved grant of 1,145,200 options (20% of the total) [15][24] Summary by Sections Purpose of the Plan - The plan aims to align the interests of shareholders, the company, and its core team, ensuring long-term development and motivation for key personnel [9][10] Management Structure - The shareholders' meeting is the highest authority for approving the plan, while the board of directors is responsible for its execution [10][11] Incentive Recipients - The plan targets executive directors, employee directors, senior management, and other key employees, with a maximum of 201 initial recipients [12][13] Source and Quantity of Shares - The shares for the stock options will come from shares repurchased from the secondary market, with specific limits on the total number of shares that can be granted [14][15] Grant and Exercise Conditions - The exercise price for the initial grant is set at 27.93 yuan per share, based on the average trading price prior to the announcement [19][20] - The plan stipulates performance-based conditions for exercising options, including group-level financial metrics [21][24] Lock-up Regulations - There are restrictions on the transfer of shares by directors and senior management during their tenure and for a period after leaving the company [19][24]

Core Viewpoint - The company is implementing an A-share option incentive plan aimed at enhancing corporate governance, attracting and retaining talent, and aligning the interests of shareholders, the company, and its core team for long-term development [3][4]. Group 1: Company Overview - Fosun Pharma was listed on the Shanghai Stock Exchange on August 7, 1998, and on the Hong Kong Stock Exchange on October 30, 2012 [2]. - As of August 22, 2025, the total share capital of the company is 2,670,429,325 shares, comprising 2,118,488,825 A-shares and 551,940,500 H-shares [2]. - The company operates in the fields of biochemical products, reagents, and related consulting services, among others [2]. Group 2: Incentive Plan Details - The total number of A-share options to be granted under the plan is capped at 5,726,100, which corresponds to 0.2144% of the company's total shares [4][5]. - The initial grant will consist of 4,580,900 options (80% of the total), while 1,145,200 options (20%) will be reserved for future grants [5][6]. - The A-share options will be sourced from shares repurchased from the secondary market [4][6]. Group 3: Objectives and Benefits - The plan aims to improve corporate governance and establish a long-term incentive mechanism to motivate executives and employees [3][4]. - It seeks to align the interests of shareholders, the company, and its core team, fostering a collective focus on the company's long-term growth [3][4]. Group 4: Grant and Exercise Conditions - The exercise price for the initial grant of A-share options is set at 27.93 yuan per share, based on the average trading price prior to the announcement [10]. - The plan includes a waiting period before options can be exercised, with specific timelines for different tranches of options [11][12]. - The plan stipulates that the options can only be exercised if certain financial performance criteria are met, including net profit and revenue from innovative drugs [14][15]. Group 5: Financial Impact and Accounting - The total estimated expense for the initial grant of 4,580,900 A-share options is projected to be 12.14 million yuan, which will be amortized over the plan's duration [30][31]. - The plan's implementation is expected to have a positive impact on the company's performance, potentially outweighing the associated costs [31].

Core Viewpoint - Shanghai Fosun Pharmaceutical Group Co., Ltd. has approved the initial grant list for the 2025 A-share stock option incentive plan during the seventh meeting of its tenth board of directors [1] Group 1 - The company has outlined the names and positions of the proposed incentive recipients for the stock option plan [1] - The decision was made on August 22, 2025, indicating a strategic move to motivate and retain key personnel within the organization [1]

进一步完善法人治理结构，建立、健全本集团长期激励机制，保证2025年A 股期权计划的顺利推进，并在最大程度上发挥激励作用，进而确保本集团发展战 略和经营目标的实现。 二、考核原则 考核评价必须坚持公正、公开、公平的原则，严格按照本办法和激励对象的 业绩进行评价，以实现2025年A股期权计划与激励对象工作业绩、贡献紧密结合， 从而提升管理绩效，实现本公司与全体股东利益最大化。 三、考核范围 本办法适用于参与2025年A股期权计划的所有激励对象。 上海复星医药（集团）股份有限公司 2025 年 A 股股票期权激励计划实施考核管理办法 为进一步保证上海复星医药（集团）股份有限公司（以下简称"本公司"） 2025 年 A 股股票期权激励计划（以下简称"2025 年 A 股期权计划"）的顺利实 施，最大程度发挥股权激励的作用，激励本公司执行董事、职工董事、高级管理 人员及本集团（即本公司及控股子公司/单位，下同）员工勤勉工作，确保本集 团发展战略和经营目标的实现，根据法律、行政法规、规范性文件和本集团实际 情况，特制定本办法。 一、考核目的 1、本集团层面业绩考核指标总得分（X）=∑各分指标得分*对应权重。 首次授予 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 本公司擬採納2025 年H股受限制股份單位計劃及根據該計劃作出首次授予的公告》，僅供參 閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年8 月2 2 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及 ...

本计划可授予的A股期权上限为572.61万份，对应A股上限为572.61万股，分别约占公司股份总数的 0.2144%和公司A股总数(不包括A股库存股份)的0.2729%。本计划首次授予的激励对象不超过201人。首 次授予所涉A股期权的行权价格为27.93元/股。 复星医药（600196）(02196)公布，为进一步完善法人治理结构，建立、健全集团长期激励机制，吸引 和保留优秀人才，充分调动公司执行董事、职工董事、高级管理人员及集团员工的积极性，有效地将股 东利益、企业利益和集团核心团队个人利益结合在一起，使各方共同关注本集团的长远发展，并为之共 同努力奋斗，在充分保障股东利益的前提下，公司制定了2025年A股股票期权激励计划(草案)。 ...

智通财经APP讯，复星医药(02196)公布，为进一步完善法人治理结构，建立、健全集团长期激励机制， 吸引和保留优秀人才，充分调动公司执行董事、职工董事、高级管理人员及集团员工的积极性，有效地 将股东利益、企业利益和集团核心团队个人利益结合在一起，使各方共同关注本集团的长远发展，并为 之共同努力奋斗，在充分保障股东利益的前提下，公司制定了2025 年 A 股股票期权激励计划(草案)。 本计划可授予的 A 股期权上限为572.61万份，对应 A 股上限为572.61万股，分别约占公司股份总数的 0.2144%和公司 A 股总数(不包括 A 股库存股份)的 0.2729%。本计划首次授予的激励对象不超过 201 人。首次授予所涉 A 股期权的行权价格为 27.93 元/股。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《上海 復星醫藥（集團）股份有限公司2025 年A股股票期權激勵計劃首次授予激勵對象名單》，僅供 參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 中國，上海 2025 年8 月2 2 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《上海 復星醫藥（集團）股份有限公司 2025 年 A 股股票期權激勵計劃實施考核管理辦法》，僅供參 閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年8 月2 2 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui ...